Stock Track | Maravai LifeSciences Plunges 9.34% After Hours on Disappointing Q3 Results and Weak Guidance

Stock Track11-07

Shares of Maravai LifeSciences Holdings, Inc. (MRVI) tumbled 9.34% in after-hours trading on Thursday following the release of the company's third-quarter financial results, which fell short of analyst expectations. The biotechnology company reported weaker-than-anticipated revenue and adjusted EBITDA, reflecting ongoing challenges in its nucleic acid production segment.

Maravai's Q3 revenue came in at $41.6 million, significantly below the consensus estimate of $49 million and representing a 39.7% year-over-year decline. The company's adjusted EBITDA for the quarter was -$10.8 million, missing analyst projections of -$7.41 million. The disappointing results were primarily attributed to a lack of high-volume CleanCap orders and non-recurring large GMP orders in the nucleic acid production segment, which saw a 52.9% decrease in revenue.

Adding to investor concerns, Maravai provided full-year 2025 revenue guidance of approximately $185 million, which may be viewed as conservative by some market participants. However, the company did highlight some positive developments, including a 7.2% year-over-year growth in its Biologics Safety Testing segment and ongoing organizational restructuring and cost reduction initiatives. Management expressed optimism for the fourth quarter, anticipating double-digit sequential revenue growth for its TriLink business unit and aiming for improved financial results in Q4 2025 and into 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100976480?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100976480","market":"hk","top_or_hot":-1,"title":"Stock Track | Maravai LifeSciences Plunges 9.34% After Hours on Disappointing Q3 Results and Weak Guidance","media":"Stock Track","content":"<p>Shares of Maravai LifeSciences Holdings, Inc. (MRVI) tumbled 9.34% in after-hours trading on Thursday following the release of the company's third-quarter financial results, which fell short of analyst expectations. The biotechnology company reported weaker-than-anticipated revenue and adjusted EBITDA, reflecting ongoing challenges in its nucleic acid production segment.</p>\n\n<p>Maravai's Q3 revenue came in at $41.6 million, significantly below the consensus estimate of $49 million and representing a 39.7% year-over-year decline. The company's adjusted EBITDA for the quarter was -$10.8 million, missing analyst projections of -$7.41 million. The disappointing results were primarily attributed to a lack of high-volume CleanCap orders and non-recurring large GMP orders in the nucleic acid production segment, which saw a 52.9% decrease in revenue.</p>\n\n<p>Adding to investor concerns, Maravai provided full-year 2025 revenue guidance of approximately $185 million, which may be viewed as conservative by some market participants. However, the company did highlight some positive developments, including a 7.2% year-over-year growth in its Biologics Safety Testing segment and ongoing organizational restructuring and cost reduction initiatives. Management expressed optimism for the fourth quarter, anticipating double-digit sequential revenue growth for its TriLink business unit and aiming for improved financial results in Q4 2025 and into 2026.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Maravai LifeSciences Plunges 9.34% After Hours on Disappointing Q3 Results and Weak Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Maravai LifeSciences Plunges 9.34% After Hours on Disappointing Q3 Results and Weak Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 05:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Maravai LifeSciences Holdings, Inc. (MRVI) tumbled 9.34% in after-hours trading on Thursday following the release of the company's third-quarter financial results, which fell short of analyst expectations. The biotechnology company reported weaker-than-anticipated revenue and adjusted EBITDA, reflecting ongoing challenges in its nucleic acid production segment.</p>\n\n<p>Maravai's Q3 revenue came in at $41.6 million, significantly below the consensus estimate of $49 million and representing a 39.7% year-over-year decline. The company's adjusted EBITDA for the quarter was -$10.8 million, missing analyst projections of -$7.41 million. The disappointing results were primarily attributed to a lack of high-volume CleanCap orders and non-recurring large GMP orders in the nucleic acid production segment, which saw a 52.9% decrease in revenue.</p>\n\n<p>Adding to investor concerns, Maravai provided full-year 2025 revenue guidance of approximately $185 million, which may be viewed as conservative by some market participants. However, the company did highlight some positive developments, including a 7.2% year-over-year growth in its Biologics Safety Testing segment and ongoing organizational restructuring and cost reduction initiatives. Management expressed optimism for the fourth quarter, anticipating double-digit sequential revenue growth for its TriLink business unit and aiming for improved financial results in Q4 2025 and into 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRVI","symbol_name":"Maravai LifeSciences Holdings, Inc.","start_time":0,"source_url":"","article_id":"1100976480","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100976480","pubTimestamp":1762466136,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Maravai LifeSciences Holdings, Inc. (MRVI) tumbled 9.34% in after-hours trading on Thursday following the release of the company's third-quarter financial results, which fell short of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRVI":"Maravai LifeSciences Holdings, Inc."},"translate_title":"个股追踪|Maravai LifeSciences盘后暴跌9.34%，因Q3业绩令人失望且指引疲弱","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRVI":1},"content_text":"Shares of Maravai LifeSciences Holdings, Inc. (MRVI) tumbled 9.34% in after-hours trading on Thursday following the release of the company's third-quarter financial results, which fell short of analyst expectations. The biotechnology company reported weaker-than-anticipated revenue and adjusted EBITDA, reflecting ongoing challenges in its nucleic acid production segment.\nMaravai's Q3 revenue came in at $41.6 million, significantly below the consensus estimate of $49 million and representing a 39.7% year-over-year decline. The company's adjusted EBITDA for the quarter was -$10.8 million, missing analyst projections of -$7.41 million. The disappointing results were primarily attributed to a lack of high-volume CleanCap orders and non-recurring large GMP orders in the nucleic acid production segment, which saw a 52.9% decrease in revenue.\nAdding to investor concerns, Maravai provided full-year 2025 revenue guidance of approximately $185 million, which may be viewed as conservative by some market participants. However, the company did highlight some positive developments, including a 7.2% year-over-year growth in its Biologics Safety Testing segment and ongoing organizational restructuring and cost reduction initiatives. Management expressed optimism for the fourth quarter, anticipating double-digit sequential revenue growth for its TriLink business unit and aiming for improved financial results in Q4 2025 and into 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100976480","isCrawlerRequest":true}